Table 5.
Analysis of factors influencing antibody levels (Omicron BA.4/5)
| Variable | Inactivated vaccine (n = 99) | Ad5-nCoV (n = 100) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Seropositivity rates % | p | Seroconversion rates % | p | GMT (95% CI) | p | Seropositivity rates % | p | Seroconversion rates % | p | GMT (95% CI) | p | |
| Sex | 0.219 | 0.851 | 0.127 | 0.786 | 0.748 | 0.557 | ||||||
| Male | 16 (29.1) | 9 (16.4) | 60.6 (51.5–71.3) | 44 (80.0) | 40 (72.7) | 216.8 (168.1–279.7) | ||||||
| Female | 18 (40.9) | 8 (17.8) | 74.7 (59.6–93.6) | 35 (77.8) | 34 (75.6) | 244.5 (176.4–338.9) | ||||||
| Age | 0.013 | 0.108 | 0.045 | 0.193 | 0.780 | 0.670 | ||||||
| 18–59 years | 26 (44.1) | 4 (9.8) | 74.3 (61.7–89.6) | 50 (83.3) | 45 (75.0) | 265.7 (204.1–345.9) | ||||||
| 60–80 years | 8 (20.0) | 13 (22.0) | 56.4 (47.0–67.7) | 29 (72.5) | 29 (72.5) | 183.0 (134.9–248.2) | ||||||
| Body mass index (kg/m2) | 0.090 | 0.535 | 0.084 | 0.157 | 0.421 | 0.218 | ||||||
| ≤18.4 | 0 (0.0) | 0 (0.0) | 48.0 | 4 (100.0) | 4 (100.0) | 395.0 (139.3–1120) | ||||||
| 18.5–24.9 | 25 (39.1) | 12 (18.5) | 73.3 (61.9–86.8) | 40 (74.1) | 37 (68.5) | 230.7 (174.5–305.1) | ||||||
| 25.0–29.9 | 9 (30.0) | 5 (16.7) | 59.9 (47.0–76.3) | 29 (85.3) | 26 (76.5) | 188.3 (140.7–252.1) | ||||||
| ≥30.0 | 0 (0.0) | 0 (0.0) | 33.3 (22.8–48.5) | 6 (75.0) | 7 (87.5) | 378.3 (107.5–1331) | ||||||
| Underlying chronic diseases | 0.159 | 0.807 | 0.020 | 0.230 | 0.740 | 0.013 | ||||||
| Yes | 6 (23.1) | 5 (18.5) | 51.1 (38.8–67.2) | 23 (71.9) | 23 (71.9) | 159.3 (115.2–220.2) | ||||||
| No | 28 (38.4) | 12 (16.4) | 73.0 (62.8–85.0) | 56 (82.4) | 51 (75.0) | 271.5 (212.3–347.1) | ||||||
| Adverse reactions | 0.008 | 0.877 | 0.060 | 0.001 | 0.004 | 0.001 | ||||||
| Yes | 14 (56.0) | 4 (16.0) | 82.7 (63.5–107.9) | 49 (89.1) | 47 (85.5) | 304.9 (237.9–390.7) | ||||||
| No | 20 (27.0) | 13 (17.3) | 61.7 (52.9–72.1) | 30 (66.7) | 27 (60.0) | 161.2 (119.0–218.3) | ||||||
| Third dose of Inactivated vaccine | 0.757 | 0.136 | 0.567 | 0.501 | 0.519 | 0.731 | ||||||
| CoronaVac | 22 (35.3) | 12 (19.7) | 68.6 (56.8–82.8) | 55 (80.9) | 49 (72.1) | 234.5 (183.8–299.1) | ||||||
| Covilo | 12 (32.4) | 3 (8.3) | 63.1 (52.7–75.6) | 24 (75.0) | 25 (78.1) | 217.4 (150.4–314.3) | ||||||
Comparisons were analyzed by Fisher’s exact test or Chi-squared test, Cochran–Armitage test were applied to analyze categorical data. P-values of less than 0.05 were considered statistically significant.